Martin Nováček

Ceftolozane–tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial

Marin H. Kollef, Martin Nováček, Ülo Kivistik et al. · The Lancet Infectious Diseases · 2019 · 346 citations

Pharmacy, Clinical Sciences, Infectious Diseases +16

Safety, efficacy, and pharmacokinetics of gremubamab (MEDI3902), an anti-Pseudomonas aeruginosa bispecific human monoclonal antibody, in P. aeruginosa-colonised, mechanically ventilated intensive care unit patients: a randomised controlled trial

Jean Chastre, Bruno François, Marc Bourgeois et al. · Critical Care · 2022 · 93 citations · Full text

Medicine, Infectious Diseases, Pharmacotherapy +17

Efficacy and safety of suvratoxumab for prevention of Staphylococcus aureus ventilator-associated pneumonia (SAATELLITE): a multicentre, randomised, double-blind, placebo-controlled, parallel-group, phase 2 pilot trial

Bruno François, Hasan S. Jafri, Jean Chastre et al. · The Lancet Infectious Diseases · 2021 · 87 citations · Full text

Medicine, Clinical Sciences, Pharmacotherapy +11

Non-Covalent Interactions Atlas Benchmark Data Sets 3: Repulsive Contacts

Kristian Kříž, Martin Nováček, Jan Řezáč · Journal of Chemical Theory and Computation · 2021 · 71 citations

Natural Sciences, Chemistry, Physics +16

Ceftolozane/tazobactam versus meropenem in patients with ventilated hospital-acquired bacterial pneumonia: subset analysis of the ASPECT-NP randomized, controlled phase 3 trial

Jean‐François Timsit, Jennifer A. Huntington, Richard G. Wunderink et al. · Critical Care · 2021 · 46 citations · Full text

Pharmacy, Pharmacotherapy, Antimicrobial Pharmacotherapy +14